You can buy or sell Provention Bio and other stocks, options, ETFs, and crypto commission-free!
Provention Bio, Inc. Common Stock, also called Provention Bio, is a clinical-stage biopharmaceutical company, which engages in the developement of biopharmaceutical products. Read More It focuses its product line on type 1 diabetes, Crohn's disease, ulcerative colitis, and emerging viral infections. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.
Lebanon, New Jersey
52 Week High
52 Week Low
Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
OLDWICK, N.J., March 19, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update. "During 2018, we made great strides towards the achievement of our strategic goal of fundamentally changing the landscape for immune-mediated disease. In the span of twelve months, we augmente...
Simply Wall StMar 13